Skip to main content

Table 1 Baseline clinical, angiographic and procedural characteristics of acute myocardial infarction patients with preserved left ventricular systolic function according to treatment at discharge

From: Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: a prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR)

Variables, n (%)

Entire population

Matched population

ACEI

(n = 2945)

ARB

(n = 2197)

No RASI

(n = 1094)

P value

ACEI

(n = 5854)

ARB

(n = 5691)

No RASI

(n = 5630)

P value

Sex, male

2315 (78.6%)

1637 (74.5%)

869 (79.4%)

< 0.001

77.9%

77.2%

78.3%

0.360

Age, year

61.9 ± 12.2

63.5 ± 12.1

63.2 ± 12.2

< 0.001

62.6 ± 12.2

62.9 ± 12.2

62.6 ± 12.0

0.468

LV ejection fraction, %

58.1 ± 5.8

59.4 ± 6.1

58.5 ± 6.0

< 0.001

58.5 ± 5.9

58.6 ± 5.9

58.7 ± 5.9

0.313

Blood pressure, mmHg

        

 Systolic BP

135 ± 27

132 ± 26

127 ± 25

< 0.001

135 ± 27

132 ± 26

128 ± 25

< 0.001

 Diastolic BP

81 ± 16

80 ± 16

77 ± 15

< 0.001

81 ± 16

80 ± 16

78 ± 15

< 0.001

Heart rate, bpm

74 ± 16

76 ± 16

74 ± 17

0.009

74 ± 16

75 ± 16

74 ± 17

< 0.001

Final diagnosis

        

 STEMI

1435 (48.7%)

871 (39.6%)

514 (46.9%)

< 0.001

45.7%

44.7%

45.9%

0.395

 Non-STEMI

1510 (51.2%)

1326 (60.3%)

580 (53.0%)

< 0.001

54.2%

55.2%

54.0%

0.395

Risks of patients

        

 Hypertension

1388 (47.1%)

1230 (55.9%)

482 (44.0%)

< 0.001

49.3%

50.3%

48.7%

0.249

 Diabetes mellitus

660 (22.4%)

627 (28.5%)

284 (25.9%)

< 0.001

24.3%

25.9%

25.7%

0.104

 Dyslipidemia

364 (12.3%)

284 (12.9%)

142 (12.9%)

0.786

12.8%

12.4%

13.3%

0.332

 Kidney disease

358 (12.2)

322 (14.7)

162 (14.8)

0.013

12.4%

13.6%

13.3%

0.115

 eGFR-MDRD

(mL/min/1.73m2)

91.6 ± 39.8

91.5 ± 31.4

91.2 ± 45.9

0.959

91.6 ± 41.4

92.6 ± 30.8

91.7 ± 41.6

0.304

Stroke

118 (4.0%)

99 (4.5%)

51 (4.6%)

0.551

4.1%

4.1%

4.2%

0.937

 Ischemic

13 (0.4%)

14 (0.6%)

7 (0.6%)

0.574

0.5%

0.5%

0.7%

0.258

 Hemorrhagic

108 (3.6%)

88 (4.0%)

44 (4.0%)

0.780

3.7%

3.7%

3.5%

0.830

Smokers

        

 Current

1304 (44.2%)

845 (38.4%)

447 (40.8%)

< 0.001

41.7%

41.3%

41.6%

0.906

 Ex-smokers

548 (18.6%)

487 (22.1%)

218 (19.9%)

0.007

20.3%

20.7%

19.5%

0.270

Laboratory findings

        

 Glucose

158 ± 67

161 ± 70

161 ± 77

0.543

158 ± 66

161 ± 71

161 ± 80

0.074

 HbA1c

6.3 ± 1.3

6.4 ± 1.4

6.4 ± 1.4

0.032

6.3 ± 1.3

6.4 ± 1.4

6.4 ± 1.4

0.654

Angiographic and procedural characteristics

Multi-vessel disease

1512 (51.3%)

1004 (45.6%)

551 (50.3%)

< 0.001

49.1%

48.0%

49.5%

0.270

Target vessel

        

 LAD

1928 (65.4)

1370 (62.3)

703 (64.2)

0.071

64.2%

63.6%

65.3%

0.191

 LCX

1345 (45.6)

954 (43.4)

463 (42.3)

0.097

44.4%

43.9%

42.2%

0.051

 RCA

1694 (57.5)

1128 (51.3)

644 (58.8)

< 0.001

55.4%

54.6%

55.9%

0.389

 Left main

121 (4.1)

87 (3.9)

47 (4.2)

0.898

3.9%

3.4%

4.1%

0.177

Drug-eluting stents

        

 Everolimus-

1501 (50.9%)

1098 (49.9%)

525 (47.9%)

0.240

50.0%

50.9%

49.2%

0.220

 Zotarolimus-

773 (26.2)

477 (21.7)

276 (25.2)

0.001

25.4%

23.4%

25.4%

0.981

 Biolimus A9

558 (18.9%)

534 (24.3%)

228 (20.8%)

< 0.001

20.4%

21.5%

21.2%

0.280

 Sirolimus-

100 (3.3%)

79 (3.5%)

59 (5.3%)

0.010

3.7%

3.6%

3.6%

0.851

 Paclitaxel-

6 (0.2%)

1 (0.0%)

1 (0.0%)

0.273

0.1%

0.0%

0.1%

0.507

Number of stents

1.16 ± 0.40

1.17 ± 0.42

1.17 ± 0.43

0.389

1.16 ± 0.41

1.16 ± 0.42

1.17 ± 0.42

0.946

Stent diameter, mm

3.17 ± 0.44

3.14 ± 0.44

3.14 ± 0.45

0.020

3.16 ± 0.44

3.15 ± 0.44

3.16 ± 0.44

0.257

Total stent length, mm

29.1 ± 12.7

28.1 ± 12.9

28.6 ± 12.9

0.001

29.0 ± 13.0

28.7 ± 12.8

28.4 ± 12.2

0.381

Discharge medication

        

 Aspirin

2931 (99.5%)

2184 (99.4%)

1083 (98.9%)

0.156

99.5%

99.5%

99.3%

0.260

 Clopidogrel

2073 (70.3%)

1404 (63.9%)

693 (63.3%)

< 0.001

67.1%

66.5%

66.3%

0.626

 Prasugrel

302 (10.2%)

285 (12.9%)

118 (10.7%)

0.008

11.1%

11.5%

10.9%

0.593

 Ticargrelor

554 (18.8%)

497 (22.6%)

268 (24.4%)

< 0.001

21%

21.3%

21.7%

0.623

 Ca-channel blockers

136 (4.6%)

180 (8.1%)

117 (10.6%)

< 0.001

6.7%

7.0%

7.3%

0.485

 Beta-blockers

2741 (93.0%)

1921 (87.4%)

757 (69.1%)

< 0.001

87.8%

86.9%

86.3%

0.053

 Statin

2848 (96.7%)

2114 (96.2%)

1028 (93.9%)

< 0.001

96.5%

96.5%

95.7%

0.057

  1. RASI, renin angiotensin system inhibitor; IPTW, inverse probability of treatment weighting; LV, left ventricular; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; STEMI, ST segment elevation myocardial infarction; LAD, left anterior descending artery; LCX, left circumflex artery, RCA = right coronary artery
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us